← Back to Search

Low-Dose CT Screening for Lung Cancer (ILST Trial)

N/A
Waitlist Available
Led By Kwun M Fong
Research Sponsored by The University of Queensland
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Current or former smokers (defined as one who has stopped smoking for one or more years)
ECOG performance status 0 or 1
Must not have
Clinical symptoms suspicious for lung cancer e.g. hemoptysis, chest pain, weight loss
Non-curatively treated cancer outside the lung
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will help determine if CT chest scans can help reduce lung cancer deaths by finding the disease early.

Who is the study for?
This trial is for men and women aged 55-80 who are current or former smokers with a significant history of smoking (at least 30 pack-years) and an elevated risk of lung cancer. They must be able to undergo CT scans, have not had chest CTs in the past two years, no recent chemotherapy, and cannot have been previously diagnosed with lung cancer.
What is being tested?
The ILST is testing whether low-dose CT scans can effectively screen for early lung cancer in individuals at high risk due to their age and smoking history. The goal is to see if this screening method can reduce deaths from lung cancer by catching it earlier.
What are the potential side effects?
While the trial itself involves low-risk procedures, potential side effects mainly relate to exposure to radiation from the CT scan which may slightly increase the risk of developing cancer over one's lifetime.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am currently smoking or have quit smoking for at least a year.
Select...
I am fully active or can carry out light work.
Select...
My lung cancer risk is high, either by a model or because I've smoked a lot.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have symptoms like coughing up blood, chest pain, or losing weight unexpectedly.
Select...
I have cancer outside the lung that was not treated to cure.
Select...
I am too large to fit into a standard CT scanner.
Select...
I cannot lie on my back with my arms over my head for scans.
Select...
I have been diagnosed with lung cancer before.
Select...
I do not want to undergo a spiral chest CT scan.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SingleExperimental Treatment1 Intervention
Single arm only, CT screening of lung
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Low dose CT
2015
N/A
~4310

Find a Location

Who is running the clinical trial?

The University of QueenslandLead Sponsor
145 Previous Clinical Trials
68,284 Total Patients Enrolled
Kwun M FongPrincipal InvestigatorUQTRC at TPCH
Steven LamPrincipal InvestigatorBritish Columbia Cancer Agency

Media Library

Single Clinical Trial Eligibility Overview. Trial Name: NCT02871856 — N/A
Thoracic Tumors Research Study Groups: Single
Thoracic Tumors Clinical Trial 2023: Single Highlights & Side Effects. Trial Name: NCT02871856 — N/A
Single 2023 Treatment Timeline for Medical Study. Trial Name: NCT02871856 — N/A
~214 spots leftby Dec 2025